Tb4 with ciprofloxacin restores eye nerves

A June 2026 study published in Investigative Ophthalmology and Visual Science by Ebrahim, Sosne, Berger and colleagues at Wayne State University tested whether topical thymosin beta-4 (sometimes labelled TB-500 in the grey market) could improve nerve regeneration and visual outcomes when added to standard antibiotic treatment for bacterial corneal infection in mice^[1].

The answer, in this animal model, was yes. The combination of thymosin beta-4 and ciprofloxacin restored corneal nerve density to levels comparable with uninfected controls, and the mice recovered both visual acuity and contrast sensitivity. Neither treatment alone achieved the same result.

What the researchers did

The team used C57BL/6 mice whose corneas were wounded and then infected with Pseudomonas aeruginosa, a common cause of bacterial keratitis in contact-lens wearers and in agricultural and industrial eye injuries. Four treatment groups received topical applications three times daily: PBS (vehicle control), thymosin beta-4 alone, ciprofloxacin alone, or the combination of thymosin beta-4 and ciprofloxacin^[1].

The researchers measured visual acuity and contrast sensitivity using an optomotor reflex system, tested corneal sensitivity with an esthesiometer, and quantified nerve fibres using beta-III tubulin immunofluorescence staining^[1].

Key findings

The combination therapy "markedly improved visual acuity and contrast sensitivity" while achieving "significantly enhanced corneal sensitivity and nerve regeneration" compared to all other groups^[1]. Corneal nerve density and architecture in the combination group returned to the level of uninfected control eyes. Ciprofloxacin alone cleared the bacterial infection but did not restore the nerve damage. Thymosin beta-4 alone reduced inflammation but left the infection incompletely controlled.

This is the specific gap the authors set out to address. Standard antibiotic treatment for bacterial keratitis focuses on eliminating the pathogen, but corneal nerve damage and the resulting loss of sensitivity and visual quality are, as the authors note, "often overlooked" in therapeutic assessments.

Where this fits in the research line

This study is not the first from this group. Berger and Sosne at Wayne State have published a series of preclinical papers on thymosin beta-4 as an adjunct to ciprofloxacin in Pseudomonas keratitis. A 2020 paper showed that thymosin beta-4 enhances antimicrobial peptide production and works synergistically with ciprofloxacin to reduce bacterial load^[2]. A 2023 review by the same group proposed thymosin beta-4 as a "potential novel adjunct treatment for bacterial keratitis," noting that it reduces inflammatory mediators and enhances wound healing while the antibiotic handles bacterial killing^[3]. A 2024 study demonstrated that the peptide activates specialized pro-resolving lipid mediator pathways, promoting phagocytosis and clearance of dead cells during infection resolution^[4].

The new 2026 paper adds the functional outcomes, specifically vision and nerve regeneration, that earlier work in the series did not measure. That makes it a meaningful step forward within this research programme, even though it remains a single-laboratory mouse model. Readers interested in the broader preclinical tissue-repair picture may also want to see our coverage of BPC-157, another peptide with a large rodent literature but limited human trial data.

Thymosin beta-4 in clinical ophthalmology

Separately from the bacterial keratitis work, thymosin beta-4 has been tested in human eyes. A 2023 Phase 3 trial of RGN-259 (a 0.1% thymosin beta-4 ophthalmic solution developed by RegeneRx and ReGenTree) in neurotrophic keratopathy reported complete corneal healing at four weeks in 6 of 10 treated patients versus 1 of 8 on placebo^[5]. That trial addressed a different condition (nerve-damage-driven corneal defects, not infection), but it is the closest human evidence for thymosin beta-4's corneal repair properties.

Limitations to keep in mind

This is a mouse study, not a human trial. The Pseudomonas keratitis model is well established in ophthalmology research, but the severity of infection and the immune response differ between mice and humans. Topical dosing in a mouse eye does not translate directly to human dosing. The sample sizes are small, as is standard for this type of mechanistic animal work. This gap between animal promise and human proof is a recurring theme across the peptide space, visible in the research on BPC-157 and TB-500 alike.

All the published work on thymosin beta-4 in bacterial keratitis comes from one research group at Wayne State University. Independent replication by other laboratories has not yet occurred. The path from these preclinical results to a human clinical trial in infected eyes would require toxicology studies, formulation work, and regulatory clearance that have not been reported.

What this means for readers

The study adds to the evidence that thymosin beta-4 has biological activity in corneal tissue repair, a line of research that stretches back more than two decades^[6]. For readers following thymosin beta-4 / TB-500, this is a preclinical finding in a legitimate research programme with a clear mechanism and functional endpoints. It is not a clinical result, and it does not support self-treatment of eye infections with grey-market peptide products.

This article is for informational purposes only and does not constitute medical advice. If you have a corneal infection or eye injury, seek immediate care from a qualified ophthalmologist.